Racura Oncology Ltd
Company Profile
Business description
Racura Oncology Ltdis a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura's primary asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that functions by binding to G4-DNA and RNA, resulting to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent researchs made by the company have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications.
Contact
1 Macquarie Place
Level 36
Gateway
SydneyNSW2000
AUST: +61 280513043
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
stocks
Magellan Financial Group: A dilutive acquisition of Barrenjoey
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,297.20 | 123.30 | -1.31% |
| CAC 40 | 8,197.77 | 196.55 | -2.34% |
| DAX 40 | 23,878.38 | 759.62 | -3.08% |
| Dow JONES (US) | 48,904.78 | 73.14 | -0.15% |
| FTSE 100 | 10,535.10 | 245.01 | -2.27% |
| HKSE | 25,768.08 | 612.94 | -2.32% |
| NASDAQ | 22,748.86 | 80.64 | 0.36% |
| Nikkei 225 | 56,279.05 | 2,474.34 | -4.21% |
| NZX 50 Index | 13,620.21 | 50.50 | -0.37% |
| S&P 500 | 6,881.62 | 2.74 | 0.04% |
| S&P/ASX 200 | 9,077.30 | 104.40 | -1.14% |
| SSE Composite Index | 4,122.68 | 59.92 | -1.43% |